George Clinical has the breadth of expertise and clinical networks to make what is traditionally one of the most complex and time consuming therapeutic areas to conduct clinical trials, one of the most streamlined.
Heart disease is the leading cause of death in the world. It accounts for more than 17 million deaths a year and that figure is rising. George Clinical’s scientific leadership is primarily focused on developing new strategies for the prevention of heart diseases by targeting their primary risk factors such as high blood pressure and cholesterol, through drug and device interventions.
The depth of George Clinical’s therapeutic expertise places us as global experts in designing and implementing studies measuring cardiovascular co-morbidities and outcomes to the highest scientific standard.
George Clinical’s scientific leadership have an impressive track record providing evidence to effect real change in practice and policy so that our research translates into clinical practice and government policy.
Our clinical trial services in cardiovascular health include:
George Clinical’s expertise and capacity to engage with significant investigator networks, place us as one of the leading cardiovascular contract research organizations operating in this therapeutic area.
Mark Huffman is the Quentin D. Young Professor of Health Policy and Associate Professor of Preventive Medicine and Medicine-Cardiology at Northwestern University’s Feinberg School of Medicine and director of the Center for Global Cardiovascular Health within the Institute for Global Health at Northwestern. He has a secondary appointment as an Associate Professor of Food Policy at The George Institute for Global Health and Cardiovascular Medicine at the University of New South Wales, both in Sydney, Australia. He is a practicing cardiologist, researcher, and teacher interested in global cardiovascular health epidemiology, clinical trials, implementation science, health systems, and policy research and training. Mark also works across the spectrum of cardiovascular disease prevention in research on acute cardiovascular quality improvement, simplifying pharmacotherapy through fixed-dose combinations, programmatic implementation, and evaluation for large-scale hypertension control, monitoring and improving the USA and global food and medicine supply, and achieving tobacco endgame. His aim is to improve global cardiovascular health and health care, especially in low- and middle-income countries, and to bring lessons learned back home to the United States of America.
Professor Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials. She started the first Heart Failure with Preserved Ejection Fraction Programme and Women’s Heart Health Clinic in Singapore. She is the Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedical Research Council-funded research platform; and principal investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study), a multinational Asian study of heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study), as well as a multinational Asian registry of diabetes (Asian Diabetes Outcomes Registry [ADORE]) in collaboration with the American College of Cardiology’s Diabetes Collaborative Registry. She serves as a consultant on several global advisory boards for cardiovascular disease, as a member of the Executive Committees of global heart failure trials, and as an Associate Editor for Circulation and European Journal of Heart Failure.
Dr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. He received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.
Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He has authored and co-authored over 170 peer-reviewed publications, including scientific statements and position documents. He is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
John Chalmers AC FAA has an outstanding record in hypertension research, both fundamental and clinical. His groundbreaking research on the role of the brain in the development of hypertension led to his election to Fellowship of the Australian Academy of Science and helped establish Flinders University as a leading international centre in hypertension and neuroscience research.
His studies on the treatment of high blood pressure for the prevention of heart attack and stroke have changed the way patients are treated throughout the world. His work has been recognised through many awards including the Wellcome Medal, the RT Hall Prize of the Cardiac Society of Australia and New Zealand, The Zanchetti Lifetime Achievement Award of the European Society of Hypertension and the Volhard Medal of the International Society of Hypertension.
Professor Chalmers’ contribution to medical science has been acknowledged through the award of many Honorary Doctoral degrees and extensive appointments on national and international boards and advisory committees. He was appointed a Companion in the Order of Australia (AC) in 1991 and an Officer in the National Order of Merit of France in 2010.
John Chalmers remains an active researcher at The George Institute Australia, where he is a principal investigator on many research grants and chair of steering committees for major studies, mentors young clinical researchers from around the world, and continues to publish and lecture prolifically.
Anthony Rodgers is a Professor of Global Health at The George Institute. After graduating in medicine in the United Kingdom he trained in epidemiology and public health in New Zealand. He was the Principal Author of the 2002 World Health Report, the main annual publication for WHO.
Since 2003 he has led a public-private partnership developing an affordable four-in-one cardiovascular combination pill (‘polypill’), with a clinical trial program in economically developed and developing countries. His current work aims to foster similar developments designed to be ‘fit for purpose’ in low income settings.
Kazem Rahimi is the James Martin Senior Fellow in Essential Healthcare at the University of Oxford and Honorary Consultant Cardiologist at the John Radcliffe Hospital, Oxford. As the Deputy Director of The George Institute UK he leads the Essential Healthcare Programme, which aims to find practical and affordable solutions for the global health priorities of the world’s largest emerging economies, as well as the priorities of vulnerable or disadvantaged populations in established economies.
He graduated in medicine from the University of Leipzig in Germany with postgraduate training in cardiology and health services research in Leipzig, London and Oxford. Prior to joining the George Institute, in 2010, he was a Research Fellow at Oxford’s Clinical Trial Service and Epidemiological Studies Unit. His research interests include service delivery innovation in chronic disease prevention and management, large-scale complex intervention studies, and data-driven electronic decision support systems.
Bruce Neal is a Senior Director at The George Institute for Global Health; Professor of Medicine, UNSW Sydney; and Chair of the Australian Division of World Action on Salt and Health.
Dr. Neal is a UK-trained physician who has 20 years research experience in the clinical, epidemiological, and public health fields with a focus on heart disease, stroke and diabetes. Bruce has a longstanding interest in the environmental determinants of high blood pressure and the potential for changes in the food supply to deliver health gains. His work has been characterized by its focus on collaboration, quantitation, translation and impact. He holds professorial appointments at UNSW Sydney, Imperial College London, Flinders University in South Australia, an honorary appointment at the University of Sydney and chairs the Australian Division of World Action on Salt and Health. He has published some 300 scientific papers and in 2016 was identified by Thomson Reuters as one of ‘The World’s Most Influential Scientific Minds’, an acknowledgement provided to just 3000 researchers across all disciplines, worldwide. He has particular expertise in salt reduction but also a broader knowledge of food policy issues related to sugars, fats, portion size and food labelling.
Vlado Perkovic is Executive Director of The George Institute, Australia, Professor of Medicine at UNSW Sydney, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials and epidemiology, in particular in preventing the progression of kidney disease and its complications. He leads several major international clinical trials, serves on the steering committees of several others, and has led the development of George Clinical, the global clinical trials arm of The George Institute. He has been involved in developing Australian and global guidelines in kidney disease, cardiovascular risk assessment and blood pressure management.
Vlado holds a Doctor of Philosophy from the University of Melbourne and completed his undergraduate training at The Royal Melbourne Hospital. He is a member of the National Health and Medical Research Council Principal Committee on Research Translation; Chair of the International Society of Nephrology Action for Clinical Trials (ISN-ACT) group; and Fellow of the Royal Australasian College of Physicians and of the American Society of Nephrology.